CYTOTRACK APS

Their core work

CytoTrack is a Danish medical technology company developing diagnostic instruments for detecting and profiling circulating tumour cells (CTCs) in blood — the cellular fragments that break away from solid tumours and circulate in the bloodstream. Their core product is a high-sensitivity scanner that can identify rare tumour cells in a standard blood draw, enabling oncologists to monitor metastatic cancer without invasive biopsies. This "liquid biopsy" approach allows treatment decisions — which therapy, which dose — to be guided by real-time tumour cell data rather than assumptions. Their technology sits at the intersection of optical engineering, cell biology, and clinical diagnostics.

What they specialise in

How they've shifted over time

CytoTrack entered H2020 in 2015 with a narrow feasibility study (SME-1, €50K) to validate the concept of profiling tumour cells in blood for personalised cancer treatment — a proof-of-concept phase with no public keyword footprint beyond the project title. By 2018 they had progressed to a full SME-2 development grant (€1.69M) with a richly described scope: CTC detection, liquid biopsy, blood analysis, personalised medicine, and cancer diagnostics as an instrument product. The trajectory is a textbook SME instrument-to-market path: validate the science, then build and commercialise the device.

CytoTrack is moving from research validation toward a clinical-grade diagnostic product, suggesting future collaboration needs will centre on clinical validation, regulatory affairs (IVD/CE marking), and hospital or oncology network partnerships rather than basic science.

How they like to work

CytoTrack leads every project they participate in — both H2020 grants were coordinated by them, with no participation as a consortium member. Their network is extremely tight: one unique partner in one country across two projects, which is characteristic of a focused SME protecting proprietary technology while using EU funding to de-risk product development. Working with them likely means entering as a service provider, clinical validation partner, or distributor rather than as a co-equal research collaborator.

CytoTrack has collaborated with just one partner across two projects, all within a single country — an unusually narrow footprint that reflects the solo-innovator SME instrument path rather than a research network builder. Their EU project history offers no visible links to clinical institutions, university labs, or international consortia.

What sets them apart

CytoTrack occupies a very specific niche: instrument-level CTC detection for clinical liquid biopsy, developed as a standalone diagnostic device rather than a lab assay or software platform. Unlike most academic CTC research groups, they are a commercial entity building a product intended for oncology departments, which means they bring both the technology and a commercialisation agenda to any partnership. For consortium builders in personalised medicine or precision oncology, they offer a rare combination of proprietary hardware, disease-specific focus, and SME agility.

Highlights from their portfolio

• CytoPro
  The largest grant (€1.69M, SME-2) represents the full product development phase, with the ambitious stated goal of saving 3,000 years of human lives annually — signalling a device targeting high-volume metastatic cancer monitoring in clinical settings.
• CYTOPRO
  The 2015 SME-1 feasibility study (€50K) established the scientific and commercial case that unlocked the later €1.69M development grant, making it the foundational step in their EU-funded instrument pathway.